Avenna Precision Medicine Technologies for Inflammatory Diseases

At Avenna we translate and commercialise most promising technologies for early detection and treatment personalisation for inflammatory Diseases. This is to make precision medicine approach for IDs affordable and scalable.

Our current focus is to translate our invitro diagnostic platform technology- GlyHealth- into clinical practice.

GlyHealth is a family of prognostic and predictive medical glycomics biomarkers to reliably measure to track chronic inflammation trajectory even at early disease stages. It can help predict future disease course and inform treatment selection for chronic and acute inflammatory diseases.

The presentation below is from our webinar at the Wuxi Healthcare Forum in March 2021. It gives an overview of our unique GlyHealth technology, the underlying science, and applications for clinicians and biopharma companies: